Form 4: Krystal Biotech Executive Suma Krishnan Executes Stock Sales Under 10b5-1 Trading Plan

Suma Krishnan, a Director and Officer at Krystal Biotech, sold shares of common stock on March 13, 2025, under a pre-arranged Rule 10b5-1 trading plan.

Summary

• Suma Krishnan, President of R&D and a Director at Krystal Biotech, sold shares of the company's common stock on March 13, 2025.
• The sales were executed under a pre-arranged Rule 10b5-1 trading plan adopted on June 13, 2024, which started on September 12, 2024, and will terminate on September 13, 2025.
• The plan contemplates quarterly sales of 25,000 shares of common stock with a limit price of $150.00 per share.
• Krishnan sold shares in multiple transactions at prices ranging from $175.30 to $179.70.
• The spouse of Suma Krishnan, Krish S. Krishnan, also sold shares under a similar 10b5-1 trading plan.
• Following the reported transactions, Suma Krishnan directly owns 1,463,711 shares and indirectly owns 140,000 shares through trusts, while her spouse indirectly owns 1,533,056 shares.

Sentiment

Score: 6

Explanation: The sentiment is neutral as the filing represents routine transactions under a pre-arranged trading plan. There is no indication of positive or negative news about the company's performance.

Future Outlook

The Rule 10b5-1 trading plan will continue to operate until September 13, 2025, with contemplated quarterly sales of 25,000 shares of common stock with a limit price of $150.00 per share.

Industry Context

The filing indicates routine transactions under a pre-arranged trading plan, which is a common practice for corporate insiders to diversify their holdings while avoiding accusations of trading on non-public information. The use of 10b5-1 plans is widespread among executives at publicly traded companies.

Comparison to Industry Standards

• Comparing Krystal Biotech to similar gene therapy companies like CRISPR Therapeutics, Editas Medicine, and Intellia Therapeutics, insider selling is a common occurrence, especially after periods of significant stock appreciation.
• The volume of shares sold by Suma Krishnan and her spouse is relatively small compared to the overall outstanding shares of Krystal Biotech, suggesting it's more likely for personal financial planning rather than a negative signal about the company's prospects.
• The use of a 10b5-1 plan aligns with industry best practices for insider trading compliance, similar to plans used by executives at companies like Amgen and Gilead Sciences.

Stakeholder Impact

• The stock sales could have a minor impact on shareholders due to the increased supply of shares in the market.
• However, since the sales are part of a pre-arranged plan, the impact is likely to be minimal.

Key Dates